| Literature DB >> 30793530 |
Bo Zhang1,2, Qiong Wu1,2, Ziheng Wang2,3, Ran Xu1, Xinyi Hu3, Yidan Sun4, Qiuhong Wang2, Fei Ju2, Shiqi Ren3, Chenlin Zhang5, Lin Qin6, Qianqian Ma7, You Lang Zhou2.
Abstract
BACKGROUND: Kidney renal clear cell carcinoma (KIRC) is the most common subtype of renal tumor. However, the molecular mechanisms of KIRC pathogenesis remain little known. The purpose of our study was to identify potential key genes related to the occurrence and prognosis of KIRC, which could serve as novel diagnostic and prognostic biomarkers for KIRC.Entities:
Keywords: bioinformatics analysis; candidate small molecules; kidney renal clear cell carcinoma; novel biomarkers
Mesh:
Substances:
Year: 2019 PMID: 30793530 PMCID: PMC6503072 DOI: 10.1002/mgg3.607
Source DB: PubMed Journal: Mol Genet Genomic Med ISSN: 2324-9269 Impact factor: 2.183
Figure 1The workflow of this study for identifying key genes and pathways in KIRC
Figure 2(A) Volcano plot of gene expression profile data between KIRC and normal tissues in each dataset. Red dots: significantly upregulated genes in KIRC; Green dots: significantly downregulated genes in KIRC; Black dots: nondifferentially expressed genes. p < 0.05 and |log2 FC|>1 were considered as significant. (B) a. Venn diagram of 503 overlap DEGs from GSE781, GSE6344, and GSE100666 datasets. b. Upregulated overlap DEGs; c. Downregulated overlap DEGs
Figure 3Functional and signaling pathway analysis of the overlapped DEGs in KIRC. (a) Biological processes (b) Cellular components (c) Molecular function (d) KEGG pathway
Functional and pathway enrichment analysis of the overlap DEGs
| Category | Term |
|
|---|---|---|
| GOTERM_BP_FAT | GO:0007588~excretion | 2.32E−09 |
| GOTERM_BP_FAT | GO:0006952~defense response | 6.27E−09 |
| GOTERM_BP_FAT | GO:0009611~response to wounding | 1.32E−08 |
| GOTERM_BP_FAT | GO:0006955~immune response | 2.22E−07 |
| GOTERM_BP_FAT | GO:0032101~regulation of response to external stimulus | 6.55E−07 |
| GOTERM_CC_FAT | GO:0044459~plasma membrane part | 9.91E−13 |
| GOTERM_CC_FAT | GO:0005887~integral to plasma membrane | 3.18E−11 |
| GOTERM_CC_FAT | GO:0031226~intrinsic to plasma membrane | 9.96E−11 |
| GOTERM_CC_FAT | GO:0005886~plasma membrane | 5.00E−08 |
| GOTERM_CC_FAT | GO:0005626~insoluble fraction | 2.16E−07 |
| GOTERM_MF_FAT | GO:0042802~identical protein binding | 3.31E−06 |
| GOTERM_MF_FAT | GO:0,046,983 ~ protein dimerization activity | 1.33E−05 |
| GOTERM_MF_FAT | GO:0042803~protein homodimerization activity | 1.54E−05 |
| GOTERM_MF_FAT | GO:0005539~glycosaminoglycan binding | 2.85E−05 |
| GOTERM_MF_FAT | GO:0030246~carbohydrate binding | 4.20E−05 |
| KEGG_PATHWAY | hsa00280:Valine, leucine and isoleucine degradation | 1.49E−05 |
| KEGG_PATHWAY | hsa00640:Propanoate metabolism | 5.26E−05 |
| KEGG_PATHWAY | hsa04610:Complement and coagulation cascades | 7.77E−04 |
| KEGG_PATHWAY | hsa00650:Butanoate metabolism | 0.003257 |
| KEGG_PATHWAY | hsa04514:Cell adhesion molecules (CAMs) | 0.005074 |
Figure 4Protein–protein interaction networks construction and module analysis
Functional and pathway enrichment analysis of genes in the most significant modules
| ID | Pathway description | Observed gene count | False discovery rate |
|---|---|---|---|
| hsa280 | Valine, leucine and isoleucine degradation | 9 | 3.19E−15 |
| hsa640 | Propanoate metabolism | 6 | 1.13E−09 |
| hsa71 | Fatty acid degradation | 6 | 4.99E−09 |
| hsa1212 | Fatty acid metabolism | 6 | 7.49E−09 |
| hsa1100 | Metabolic pathways | 13 | 4.30E−07 |
| hsa650 | Butanoate metabolism | 4 | 3.44E−06 |
| hsa380 | Tryptophan metabolism | 4 | 1.60E−05 |
| hsa1200 | Carbon metabolism | 5 | 1.81E−05 |
| hsa310 | Lysine degradation | 4 | 3.44E−05 |
| hsa4060 | Cytokine–cytokine receptor interaction | 6 | 7.84E−05 |
Figure 5(a) The heatmap of module genes between KIRC and normal samples. (b) The biological process of module genes analyzed by BiNGO. The color depth of nodes represents the corrected p‐value. The size of nodes represents the number of genes involved
Figure 6The expression level of hub genes between KIRC and normal tissues in three datasets
Figure 7(a) The expression of hub genes between KIRC tissues and normal tissues. (b) The prognostic value of hub genes
Figure 8Representative immunohistochemistry staining results reveal the protein level expression of hub genes in KIRC and normal tissues
Figure 9(a) The network of module genes and their coexpression genes constructed by cBioPortal. Nodes with thick outline: hub genes; Nodes with thin outline: coexpression genes. (b) Pop plot of top 20 identified small molecules that could reverse the gene expression of KIRC
List of the 20 most significant small molecule drugs that can reverse the tumoral status of KIRC
| CMap name | Enrichment |
|
|---|---|---|
| Pipemidic acid | −0.853 | 0.00637 |
| Dicloxacillin | −0.819 | 0.00203 |
| Harmalol | −0.817 | 0.01216 |
| Cromoglicic acid | −0.794 | 0.08303 |
| Ikarugamycin | −0.773 | 0.024 |
| Fasudil | −0.749 | 0.12454 |
| Memantine | −0.742 | 0.00871 |
| TTNPB | −0.703 | 0.17597 |
| Prestwick−675 | −0.696 | 0.01814 |
| Tocainide | −0.687 | 0.02085 |
| (‐)‐Atenolol | −0.648 | 0.03648 |
| Urapidil | −0.642 | 0.03957 |
| Convolamine | −0.635 | 0.04323 |
| Dimenhydrinate | −0.626 | 0.04812 |
| CP−863187 | −0.626 | 0.04846 |
| Aminoglutethimide | −0.622 | 0.11319 |
| Brinzolamide | −0.614 | 0.05602 |
| Ticarcillin | −0.612 | 0.12627 |
| Coralyne | −0.609 | 0.05954 |
| Strophanthidin | −0.601 | 0.06595 |